Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hua Medicine ( (HK:2552) ) has shared an update.
Hua Medicine announced the grant of 20 million share options to three executive directors and 71 employees under its share option scheme. This initiative aims to reward outstanding performance and align employee interests with company growth, with vesting contingent on achieving specific revenue targets over the next three years, reinforcing long-term commitment without a clawback mechanism.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. The company is listed on the Hong Kong Stock Exchange and is engaged in creating novel therapies for diabetes and other metabolic diseases.
YTD Price Performance: 131.51%
Average Trading Volume: 6,572,455
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.28B
Find detailed analytics on 2552 stock on TipRanks’ Stock Analysis page.